Targeting IL-6 signaling by monoclonal antibody siltuximab attenuates cholangiocarcinoma growth. Nguyen MLT, Bui KC, Scholta T, Xing J, et al. J Gastroenterol Hepatol 2020 Oct 22. doi: 10.1111/jgh.15307.

Read + Share

Amedeo Smart

Independent Medical Education

Nguyen MLT, Bui KC, Scholta T, Xing J, et al. Targeting IL-6 signaling by monoclonal antibody siltuximab attenuates cholangiocarcinoma growth. J Gastroenterol Hepatol 2020 Oct 22. doi: 10.1111/jgh.15307.
PMID: 33091158